Cookies

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.


Durham Research Online
You are in:

Antimicrobial peptides for leishmaniasis.

Cobb, S.L. and Denny, P.W. (2010) 'Antimicrobial peptides for leishmaniasis.', Current opinion in investigational drugs., 11 (8). pp. 868-875.

Abstract

Leishmaniasis is a parasitic disease that is endemic to American, African, Asian and southern European countries. More than 350 million individuals in 88 countries are at risk of infection from this neglected tropical disease. No effective vaccinations are available against leishmaniasis, and control of the disease relies entirely on toxic drug treatments, some of which were developed as early as the 1940s. As parasite resistance becomes more prevalent, there is increasing concern that currently used drugs will soon become ineffective treatments. Consequently, an urgent need exists to develop new classes of compounds that are active against drug-resistant strains of Leishmania. This review summarizes research aimed at investigating the potential development of antimicrobial peptide-based antileishmanial agents.

Item Type:Article
Keywords:AMP, Antileishmanial, Antimicrobial peptide, Drug resistance, Leishmania, Leishmaniasis, Therapy.
Full text:(AM) Accepted Manuscript
Download PDF
(393Kb)
Status:Peer-reviewed
Publisher Web site:https://www.ncbi.nlm.nih.gov/labs/articles/20721829/
Record Created:06 Aug 2010 10:05
Last Modified:14 Feb 2018 11:38

Social bookmarking: del.icio.usConnoteaBibSonomyCiteULikeFacebookTwitterExport: EndNote, Zotero | BibTex
Look up in GoogleScholar | Find in a UK Library